Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Aditi R SaxenaJuan P FriasDonal N GormanRene N LopezNabil AndrawisNikolaos TsamandourasMorris J BirnbaumPublished in: Diabetes, obesity & metabolism (2023)
gov identifier: NCT04617275.